ConductScience.org, home

Paper28314920

[New antibiotics - standstill or progress].

Rademacher J and 1 other. Med Klin Intensivmed Notfmed, 2017. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. [New antibiotics - standstill or progress]. Papers, record 28314920. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28314920

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
[New antibiotics - standstill or progress].
PubMed
Journal
Med Klin Intensivmed Notfmed
PubMed
Year
2017
PubMed
Publication types
Comparative Study, Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.32
iCite
Revised in PubMed
2026-01-27
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rademacher JJ
2Welte TT

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
Bacterial InfectionsMajor topic
Drug ApprovalMajor topic
Drug Resistance, Multiple, BacterialMajor topic
Azabicyclo Compounds
Ceftazidime
Cephalosporins
Clinical Trials as Topic
Drug Combinations
Ephedrine
Humans
Macrolides
Methicillin-Resistant Staphylococcus aureus
Organophosphates
Oxazoles
Penicillanic Acid
Phenobarbital
Staphylococcal Infections
Tazobactam
Theophylline
Triazoles
Ceftaroline

Source PubMed

Download CSV of topics

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122247123Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.Clin Infect Dis2012https://conductscience.org/library/papers/22247123PubMed
225931244Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).Lancet2015https://conductscience.org/library/papers/25931244PubMed
324580739European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.Clin Microbiol Infect2014https://conductscience.org/library/papers/24580739PubMed
419085949Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases.Hepatology2009https://conductscience.org/library/papers/19085949PubMed
527107460
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Lancet Infect Dis2016https://conductscience.org/library/papers/27107460PubMed
624909499Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.Lancet Infect Dis2014https://conductscience.org/library/papers/24909499PubMed
723391714
Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
J Antimicrob Chemother2013https://conductscience.org/library/papers/23391714PubMed
823507282
Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.
Antimicrob Agents Chemother2013https://conductscience.org/library/papers/23507282PubMed
925539586
Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
Lancet Infect Dis2015https://conductscience.org/library/papers/25539586PubMed
1026962078
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Clin Infect Dis2016https://conductscience.org/library/papers/26962078PubMed
1123403680Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.JAMA2013https://conductscience.org/library/papers/23403680PubMed
1224723282A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.Clin Infect Dis2014https://conductscience.org/library/papers/24723282PubMed
1325670823Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).Clin Infect Dis2015https://conductscience.org/library/papers/25670823PubMed
1423145859
Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.
Curr Med Res Opin2012https://conductscience.org/library/papers/23145859PubMed
1524615816Dramatic increase in vancomycin-resistant enterococci in Germany.J Antimicrob Chemother2014https://conductscience.org/library/papers/24615816PubMed

Download CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
35982884Acquaintance and Awareness of Budding Physicians toward Antimicrobials' Use: Need of the Hour.J Lab Physicians2022https://conductscience.org/library/papers/35982884PubMed
31546812Antibiotic Use: A Cross-Sectional Study Evaluating the Understanding, Usage and Perspectives of Medical Students and Pathfinders of a Public Defence University in Malaysia.Antibiotics (Basel)2019https://conductscience.org/library/papers/31546812PubMed
28613234Synthesis and Bioactivity Evaluation of N-Arylsulfonylindole Analogs Bearing a Rhodanine Moiety as Antibacterial Agents.Molecules2017https://conductscience.org/library/papers/28613234PubMed
28593351
[What is the perception of the 10-point plan of the German Federal Ministry of Health against multidrug-resistant pathogens and measures of antibiotic stewardship? : An interdisciplinary analysis among German clinicians and development of a decision tool for urologists].
Urologe A2017https://conductscience.org/library/papers/28593351PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28314920

GET https://conductscience.org/api/papers/v1/28314920/authors